Teicoplanin Injectable (Iv/Im) Suppliers & Bulk Manufacturers
Available Forms: Injectable (IV/IM)
Available Strengths: 200 mg/100 mL, 400 mg/200 mL, 400 mg/100 mL
Reference Brands: Targocid, Tolocin(US & EU)
Category:
Antibiotics
Teicoplanin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, causing bacterial lysis. It is effective against gram-positive bacteria, including MRSA. Benefits include long half-life allowing once-daily dosing, rapid bacterial eradication, and safety for severe infections like endocarditis and osteomyelitis, when used properly under supervision.
Teicoplanin Injectable (IV/IM) is available in Injectable (IV/IM)
and strengths such as 200 mg/100 mL, 400 mg/200 mL, 400 mg/100 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Teicoplanin Injectable (IV/IM) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Teicoplanin Injectable (IV/IM) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Teicoplanin injectable is approved in the EU and US for severe gram-positive bacterial infections, including MRSA. In the EU, brands like Targocid are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, approval is limited, with extraregional use mainly in Europe and Asia. Both regions require detailed dossiers, including clinical trial data, manufacturing practices, and pharmacovigilance plans for approval and ongoing safety. For expert support on regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for teicoplanin IV formulations, ensuring adherence to European and US standards for safe, effective antimicrobial therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing